1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd.

300363.SZ
Porton Pharma Solutions Ltd.CN flagShenzhen Stock Exchange
18.18
CNY
+0.21
- -
9.88BMarket Cap
Porton Pharma Solutions Ltd.
300363.SZ
(Shenzhen Stock Exchange)

Recent

price

18.18

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.52
1.54
1.9
2.03
2.52
2.5
3.18
2.75
2.47
2.93
3.9
5.75
12.98
6.73
5.55
6.39
7.66
Revenue per Share
0.14
0.17
0.22
0.28
0.32
0.27
0.41
0.25
0.26
0.35
0.61
0.97
3.7
0.49
-0.53
0.18
-0.21
Basic EPS, GAAP
- -
-0.04
-0.04
-0.2
-0.55
-0.76
0.23
0.31
0.05
0.33
0.21
-0.55
2.57
-0.92
-0.16
0.87
-0.98
Free Cash Flow per Basic Share
0.01
0.01
0.03
0.02
0.07
0.12
0.13
0.18
0.16
0.13
0.16
0.15
0.24
1.15
0.56
0.06
0.09
Dividend per Share
0.38
0.49
0.69
0.94
1.17
2.1
2.38
2.47
2.7
2.72
3.14
3.82
7.2
6.55
5.55
5.81
7.1
Book Value per Share
0.48
0.59
0.81
1.1
2.02
2.24
2.67
2.51
5.32
5.15
5.76
6.99
10.84
10.16
8.95
9.26
11.51
Tangible Book Value per Share
299
360
363
361
392
409
418
430
479
530
532
540
542
545
543
535
428
Basic Weighted Avg Shares
456
553
690
734
987
1,021
1,327
1,184
1,185
1,551
2,072
3,105
7,035
3,667
3,012
3,420
3,281
Sales/Revenue/Turnover
15.01
15.47
17.38
18.31
17.88
14.62
19.86
15.97
11.17
14.41
19.79
20.53
32.5
9.25
-4.78
6.17
4.31
Operating Margin (%)
11
13
15
18
30
56
79
116
125
117
131
192
260
349
401
426
- -
Depreciation Expense
43
62
80
100
125
110
171
107
124
186
324
524
2,005
267
-288
96
-91
Net Income, GAAP
23.48
21.7
19.15
16.36
17.09
19.83
20.89
17.64
16.13
7.13
11.15
13.35
13.78
28.81
- -
63.25
16.6
Effective Tax Rate (%)
9.44
11.29
11.64
13.64
12.71
10.81
12.9
9.07
10.51
11.96
15.66
16.87
28.51
7.28
-9.55
2.82
-2.76
Profit Margin (%)
21
55
54
-48
-75
-118
-205
-84
1,526
1,279
1,175
1,092
2,447
2,263
1,536
1,478
1,501
Working Capital
53
57
78
33
93
310
184
422
255
242
189
231
520
1,692
1,505
1,013
1,316
LT Debt
163
246
328
428
874
1,180
1,370
1,449
2,883
3,064
3,393
4,186
6,472
6,100
5,411
5,498
5,474
Total Equity
21.89
19.01
20.57
18.76
14.53
7.22
9.53
6.47
3.44
5.58
9.99
12.54
31.9
3.11
- -
1.09
- -
Return on Invested Capital (%)
21.37
23.48
22.57
20.79
18.06
10.25
11.04
7.63
8.38
10.92
17.48
22.75
50.54
7
- -
3.63
2.13
Return on Capital (%)
51.05
42.86
37.7
34.03
31.47
16.8
18.51
10.45
10.57
13.57
20.86
28.07
67.24
7.15
-8.74
3.15
-2.94
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
451
443
659
LT Borrowings
909
931
746
LT Finance Leases
596
585
571
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
545
545
545
Market Capitalization
8,801
7,540
7,317

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,241
3,129
3,201
Cash, Cash Equivalents & STI
1,475
1,441
1,543
Accounts Receivable, Net
796
766
763
Inventories
771
724
702
Total Current Liabilities
1,705
1,525
1,700
Payables & Accruals
- -
- -
- -
ST Debt
451
443
659
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.04%
12.51%
1.61%
Free Cash Flow
-142.34%
-360.53%
-646.05%
Net Income, GAAP
7.39%
-16.75%
-133.48%
Sales/Revenue/Turnover
20.79%
24.84%
13.54%
Total Cash Common Dividend
36.3%
59.96%
-90.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
678
674
773
887
3,012
2025
801
820
875
- -
3,420
2026
886
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
- -
- -
- -
-0.53
2025
-0.01
- -
- -
- -
0.18
2026
0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
0.56
2025
0.02
- -
- -
- -
0.06
2026
0.01
- -
- -
- -
- -
Similar Companies
Rapport Therapeutics, Inc. Common Stock (RAPP)
Cerecor Inc. (CERC)
Abeona Therapeutics Inc. (ABEO)
Dimension Therapeutics, Inc. (DMTX)
Liminatus Pharma, Inc. Warrants (LIMNW)
LadRx Corporation (CYTR)
Business
Porton Pharma Solutions Ltd. (300363.SZ) is a leading contract development and manufacturing organization (CDMO) providing end-to-end services for small molecule drugs, peptide and oligonucleotide drugs, biologics and conjugates including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs) and peptide-drug conjugates (PDCs), and advanced therapy medicinal products such as gene and cell therapies; its core offerings encompass active pharmaceutical ingredients (APIs), drug substances (DS), drug products (DP), process development, GMP manufacturing from preclinical to commercial scale, and one-stop solutions for global pharmaceutical and biotech companies, research institutions, and clinical trials. Founded in 2005 and headquartered in Chongqing, China, with additional headquarters in Shanghai, the company operates R&D centers and production sites across China (including Sichuan, Jiangsu, Jiangxi, Hubei, and Suzhou), the United States (New Jersey), Slovenia, Belgium, Switzerland, and Denmark, employing over 4,900 staff globally and serving more than 1,000 clients including 80% of the top 20 pharmaceutical firms. Formerly known as Porton Fine Chemicals Ltd., it changed its name to Porton Pharma Solutions Ltd. in January 2018 to reflect its expanded CDMO scope. Recent developments include a strategic partnership with Dragon Sail Pharmaceutical in December 2024 to build an ADC drug development and production ecosystem through resource integration and supply chain sharing; a strategic alliance with Shanghai InnoStar Bio-tech in October 2024 for non-clinical research and end-to-end CDMO collaboration to accelerate drug development and enhance global market competitiveness; acquisition of 100% of Shanghai Gateway Pharmaceutical in 2022 to bolster CRO capabilities, R&D-production integration, and overall CDMO capacity; a strategic cooperation with Porton Biotech and Tianyu Life in September for NK cell therapy research, process development, GMP production, and clinical approval support; recognition as an excellent supplier by Mednovo Group in 2025 for radionuclide-drug conjugate (RDC) R&D support; opening of its small molecule platform headquarters and R&D center in Shanghai's Minhang District in May 2023 spanning 22,000 square meters; and Series-A financing closure for subsidiary Suzhou Porton Biologics in 2025 to expand commercial production of gene and cell therapy products including plasmids, viral vectors, and AAV processes.